M&A Lab
November 13, 2008
Ranbaxy-Daiichi Deal Dissected

Dear All,

With the completion of acquisition of 63.92% equity stake in Ranbaxy Laboratories Limited (“Ranbaxy”), India's largest pharmaceutical company, by Japanese pharma major Daiichi Sankyo Co., Ltd. (“Daiichi”), on November 7, 2008, it would be interesting to analyze the key legal and tax issues that arose from the beginning till the completion of this landmark deal.

For a detailed analysis of the legal and tax issues, please click here for the document.

As you would be aware, we have been providing regular information on latest legal developments. M&A Lab is our latest initiative to provide you in depth and knowledge based analysis of latest M&A deals. We will be happy to have your views / comments on our initiative.


– Ruchi Biyani, Vaidhyanadhan Iyer & Nishchal Joshipura 
You can direct your queries or comments to Team M&A

Disclaimer

The contents of this hotline should not be construed as legal opinion. View detailed disclaimer.

This Hotline provides general information existing at the time of preparation. The Hotline is intended as a news update and Nishith Desai Associates neither assumes nor accepts any responsibility for any loss arising to any person acting or refraining from acting as a result of any material contained in this Hotline. It is recommended that professional advice be taken based on the specific facts and circumstances. This Hotline does not substitute the need to refer to the original pronouncements.

This is not a Spam mail. You have received this mail because you have either requested for it or someone must have suggested your name. Since India has no anti-spamming law, we refer to the US directive, which states that a mail cannot be considered Spam if it contains the sender's contact information, which this mail does. In case this mail doesn't concern you, please unsubscribe from mailing list.

NDA Connect

Connect with us at events, 
conferences and seminars.

M&A Lab

November 13, 2008

Ranbaxy-Daiichi Deal Dissected

Dear All,

With the completion of acquisition of 63.92% equity stake in Ranbaxy Laboratories Limited (“Ranbaxy”), India's largest pharmaceutical company, by Japanese pharma major Daiichi Sankyo Co., Ltd. (“Daiichi”), on November 7, 2008, it would be interesting to analyze the key legal and tax issues that arose from the beginning till the completion of this landmark deal.

For a detailed analysis of the legal and tax issues, please click here for the document.

As you would be aware, we have been providing regular information on latest legal developments. M&A Lab is our latest initiative to provide you in depth and knowledge based analysis of latest M&A deals. We will be happy to have your views / comments on our initiative.


– Ruchi Biyani, Vaidhyanadhan Iyer & Nishchal Joshipura 
You can direct your queries or comments to Team M&A

Disclaimer

The contents of this hotline should not be construed as legal opinion. View detailed disclaimer.

This Hotline provides general information existing at the time of preparation. The Hotline is intended as a news update and Nishith Desai Associates neither assumes nor accepts any responsibility for any loss arising to any person acting or refraining from acting as a result of any material contained in this Hotline. It is recommended that professional advice be taken based on the specific facts and circumstances. This Hotline does not substitute the need to refer to the original pronouncements.

This is not a Spam mail. You have received this mail because you have either requested for it or someone must have suggested your name. Since India has no anti-spamming law, we refer to the US directive, which states that a mail cannot be considered Spam if it contains the sender's contact information, which this mail does. In case this mail doesn't concern you, please unsubscribe from mailing list.

NDA Connect

Connect with us at events, 
conferences and seminars.